Literature DB >> 10394361

Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions.

O T Fackler1, W Luo, M Geyer, A S Alberts, B M Peterlin.   

Abstract

Nef of primate lentiviruses is critical for high levels of viremia and the progression to AIDS. Nef associates with and activates a serine/threonine kinase (Nef-associated kinase [NAK]) via the small GTPases Rac1 and Cdc42. We identified the protooncogene and guanine nucleotide exchange factor Vav as the specific binding partner of Nef proteins from HIV-1 and SIV. The interaction between Nef and Vav led to increased activity of Vav and its downstream effectors. Both cytoskeletal changes and the activation of c-Jun N-terminal kinase (JNK) were observed. Furthermore, a dominant-negative Vav protein inhibited NAK activation and viral replication. Thus, the interaction between Nef and Vav initiates a signaling cascade that changes structural and physiological parameters in the infected cell.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10394361     DOI: 10.1016/s1097-2765(01)80005-8

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  100 in total

1.  Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions.

Authors:  L X Liu; N Heveker; O T Fackler; S Arold; S Le Gall; K Janvier; B M Peterlin; C Dumas; O Schwartz; S Benichou; R Benarous
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

2.  The Nef protein of HIV-1 associates with rafts and primes T cells for activation.

Authors:  J K Wang; E Kiyokawa; E Verdin; D Trono
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 3.  Structure--function relationships in HIV-1 Nef.

Authors:  M Geyer; O T Fackler; B M Peterlin
Journal:  EMBO Rep       Date:  2001-07       Impact factor: 8.807

4.  Distinct trafficking pathways mediate Nef-induced and clathrin-dependent major histocompatibility complex class I down-regulation.

Authors:  S Le Gall; F Buseyne; A Trocha; B D Walker; J M Heard; O Schwartz
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 5.  HIV-1 Nef control of cell signalling molecules: multiple strategies to promote virus replication.

Authors:  Alison L Greenway; Gavan Holloway; Dale A McPhee; Phoebe Ellis; Alyssa Cornall; Michael Lidman
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

6.  HIV Nef-mediated major histocompatibility complex class I down-modulation is independent of Arf6 activity.

Authors:  Jakob E Larsen; Ramiro H Massol; Thomas J F Nieland; Tomas Kirchhausen
Journal:  Mol Biol Cell       Date:  2003-11-14       Impact factor: 4.138

7.  A novel motif in HIV-1 Nef that regulates MIP-1beta chemokine release in macrophages.

Authors:  Lue Dai; Mario Stevenson
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

8.  CD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable.

Authors:  Kristin Agopian; Bangdong L Wei; J Victor Garcia; Dana Gabuzda
Journal:  Virology       Date:  2006-09-18       Impact factor: 3.616

9.  Comparative proteomic analysis of HIV-1 particles reveals a role for Ezrin and EHD4 in the Nef-dependent increase of virus infectivity.

Authors:  Christelle Brégnard; Alessia Zamborlini; Marjorie Leduc; Philippe Chafey; Luc Camoin; Ali Saïb; Serge Benichou; Olivier Danos; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

10.  HIV-1 Nef inhibits ruffles, induces filopodia, and modulates migration of infected lymphocytes.

Authors:  Cinzia Nobile; Dominika Rudnicka; Milena Hasan; Nathalie Aulner; Françoise Porrot; Christophe Machu; Olivier Renaud; Marie-Christine Prévost; Claire Hivroz; Olivier Schwartz; Nathalie Sol-Foulon
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.